Sanofi has begun construction of a cutting-edge insulin manufacturing facility at its BioCampus in Frankfurt, Germany, aiming for full production by 2032. This new plant will enhance Sanofi's ability to supply insulin reliably to millions worldwide, leveraging advanced automation and AI technologies. The facility, covering 36,000 square meters, will be one of Europe's largest and most advanced, supporting Sanofi's long-term commitment amid rising global diabetes cases. The project received public support from German authorities and reflects Sanofi's strategy to maintain a strong insulin supply chain for decades.
Following Sanofi's announcement of its new insulin manufacturing facility in Germany, the company's shares are trading at USD 39.96 on Pluang as of Oct 19, 2026 17:11 WIB, down 1.60% for the day. Sanofi holds a market capitalization of $96.64 billion and offers a dividend yield of 5.96%, reflecting its established position in the health sector. The typical hold time for SNY on Pluang is 94 days, indicating steady investor interest.
Novavax stock dropped 12% due to heavy selling pressure on vaccine makers, with Moderna also falling 10% while Pfizer remained stable. Novavax depends on Sanofi to commercialize its COVID vaccine, making its revenue reliant on Sanofi's rollout and mi...
Recursion Pharmaceuticals announced a $200 million oversubscribed follow-on stock offering backed by major healthcare investors. The company reported promising Phase 1b/2 data for REC-4881 showing significant and durable reductions in precancerous po...
